I would prefer Zantrene myself !
Brequinar does not have a predictable dosing regime, and has a low safety profile.
And also is not as effective as Zantrene - at least 10x less effective for FTO inhibition.
I have always thought it likely that a virulent virus & severe illness where the patient struggles to fight it off - inhibiting FTO, possible sustenance mechanism for the enduring virus (? ), may help.
You saying Brequinar is in trials suggests testing for an association with FTO, & inhibition of the mechanism of FTO, as being significant
Ann: Breakthrough Zantrene Heart Protection Discovery, page-364
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |